Skip To Main Content
Yingying Hu on Muck Rack

Yingying Hu

As seen in: Nature, Wiley Online Library, New Phytologist, Frontiers, MDPI, BMC Psychology, Royal Society of Chemistry, BioRxiv, Cell Press, Stem Cell Reports and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingying

Contact Yingying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A scoping review of artificial intelligence-enabled wearables for medication adherence

|
By Ying Chen, He Zhao, Run Xu, Yiyang Li, Shuang Cai, Yingying Hu
| Nature Verified
Abstract Medication non-adherence remains a major global public health challenge with substantial clinical and economic burden. Artificial intelligence (AI)-enabled wearables may offer new opportunities to support medication adherence management. This scoping review assesses the current evidence on AI-enabled wearables for medication adherence, focusing on their applications, performance, and clinical translation. We screened three databases for literature published up to September 18, 2025.
Open in Who Shared Issue with article?

PLA2G2F suppresses ferroptosis through phospholipid remodeling

|
By Yingying Hu, Presha Rajbhandari, Penghsuan Huang, Nicholas P. Carbone, Deguang Liang, Wei Gu, Alban Ordureau, Brent R. Stockwell, Xuejun Jiang, Joleen Csuka
| Nature Verified
Abstract Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation, and it has emerged as a potential therapeutic vulnerability of cancer. Here we identify the secretory phospholipase PLA2G2F (phospholipase A2 group IIF) as a ferroptosis suppressor in bladder cancer and elucidate its regulation and mechanism of action. PLA2G2F functions through an intracellular mechanism by localizing to the endoplasmic reticulum to inhibit ferroptosis.
Open in Who Shared Issue with article?

Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR :: ABL1 Y253H/T315I compound mutation: a case report

|
By Yingying Hu, Hongbing Ma, Xu He
| Frontiers
Abstract Compound BCR::ABL1 mutations, particularly those including T315I in combination with P-loop substitutions, represent a major therapeutic challenge in advanced-phase chronic myeloid leukemia (CML). Clinical evidence supporting dual ATP-site and allosteric inhibition in this setting remains limited.
Open in Who Shared Issue with article?
See all 38 licensed articles (43 Total)